en · de · es · fr · pt
bpc-157-notes.peptides6608.com › Guide › Background And Chemical Identity — Background and Details

Background And Chemical Identity — Background and Details

By Editorial Desk · published 2025-09-23 · last reviewed 2025-10-12 · Guide

If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-10-12. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Chemical Identity

The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.

Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.

BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.

Identity and Molecular Background

BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.

Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.

Bpc-157 at a glance

PropertyValueNotes
Molar massApproximately 1419.5 g/molCalculated from the reported 15-residue sequence
Molecular formulaC62H98N16O22Based on the same sequence
AppearanceWhite to off-white powderTypical of a lyophilized preparation
Solubility classFreely soluble in waterAlso dissolves in saline solutions
Typical storage temperatureMinus 20 degrees Celsius, dryRefrigeration advised after reconstitution

BPC-157 Handling and Analysis

Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.

Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.

BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.

Related pages on this site

Background and Molecular Identity

BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.

Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.

Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.

Background, Origin, and Naming

BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.

Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.

Research Literature and Evidence Gaps

Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.

Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.

Notes from published material

== Stimulants == A stimulant is defined as an agent (as a drug) that temporarily increases the activity central nervous system and the body. For athletes, stimulants are used for two major reasons: to heighten energy levels and to boast endurance. Examples of stimulants are: amphetamine (Adderall), caffeine (guarana), cocaine, ephedrine, fenfluramine (Fen), methamphetamine, methylphenidate (Ritalin), phentermine (Phen), synephrine (bitter orange). Stimulants phenylephrine and pseudoephedrine aren't banned. The most common abused stimulant by athletes is amphetamine.

== Further reading == Barua, Pradeep (1997). "Strategies and Doctrines of Imperial Defence: Britain and India, 1919–45". Journal of Imperial and Commonwealth History. 25 (2): 240–266. doi:10.1080/03086539708583000. Cohen, Stephen P. (May 1969). "The Untouchable Soldier: Caste, Politics, and the Indian Army". The Journal of Asian Studies. 28 (3): 453–468. doi:10.2307/2943173. JSTOR 2943173. (subscription required) Collen, Edwin H. H. (1905). "The Indian Army" . The Empire and the century. London: John Murray. pp. 663–81. Duckers, Peter (2003). The British Indian Army 1860–1914. Shire Books. ISBN 978-0-7478-0550-2. Farrington, Anthony (1982). Guide to the records of the India Office Military Department, India Office Library and Records. India Office Library and Records. ISBN 978-0-903359-30-6. Gupta, Partha Sarathi; Deshpanda, Anirudh; Yong, Tan Tai; Sundaram, Chander S.; Roy, Kaushik; Kaul, Vivien Ashima (2002). The British Raj and its Indian Armed Forces, 1857–1939. New Delhi: Oxford University Press. pp. 98–124. ISBN 0195658051. Guy, Alan J.; Boyden, Peter B. (1997). Soldiers of the Raj, The Indian Army 1600–1947. National Army Museum Chelsea. Heathcote, T. A. (1995). The Military in British India: The Development of British Land Forces in South Asia, 1600–1947. Manchester University Press. Holmes, Richard. Sahib the British Soldier in India, 1750–1914. Rose, Patrick (2017). Jeffreys, Alan (ed.). The Indian Army 1939–47: Experience and Development (1st ed.). Routledge. ISBN 978-1138110069. Mason, Philip (1974).

Vitamin A is found in many foods. Vitamin A in food exists either as preformed retinol – an active form of vitamin A – found in animal liver, dairy and egg products, and some fortified foods, or as provitamin A carotenoids, which are plant pigments digested into vitamin A after consuming carotenoid-rich plant foods, typically in red, orange, or yellow colors. Carotenoid pigments may be masked by chlorophylls in dark green leaf vegetables, such as spinach. The relatively low bioavailability of plant-food carotenoids results partly from binding to proteins – chopping, homogenizing or cooking disrupts the plant proteins, increasing provitamin A carotenoid bioavailability. Vegetarian and vegan diets can provide sufficient vitamin A in the form of provitamin A carotenoids if the diet contains carrots, carrot juice, sweet potatoes, green leafy vegetables such as spinach and kale, and other carotenoid-rich foods. In the U.S., the average daily intake of β-carotene is in the range 2–7 mg. Some manufactured foods and dietary supplements are sources of vitamin A or β-carotene.

Sources: en.wikipedia.org

Further detail

=== Properties === The chemical properties of MDMA have been described. As a free base, MDMA is a colorless oil insoluble in water. The most common salt of MDMA is the hydrochloride salt. Pure MDMA hydrochloride is water-soluble and appears as a white or off-white powder or crystal.

== Extraction == After finishing the digestion the peptides generated in this process have to be extracted from the gel matrix. This is accomplished by one or several extraction steps. The gel particles are incubated with an extraction solution and the supernatant is collected. In the first extraction, almost all of the peptide is recovered, the repetition of the extraction step can increase the yield of the whole process by only 5-10%. To meet the requirements of peptides with different physical and chemical properties an iterative extraction with basic or acidic solutions is performed. For the extraction of acidic peptides a solution similar to the concentration and composition of the digestion buffer is used; basic peptides are extracted in dependence to the intended mass spectrometric method with a low concentrated acidic solution of formic acid for ESI and trifluoroacetic acid for MALDI respectively. Studies on model proteins showed a recovery of approximately 70–80% of the expected peptide yield by extraction from the gel. Many protocols contain an additional fraction of acetonitrile to the extraction solution which, in concentrations above 30% (v/v), is effective in reducing the adsorption of peptides to the surface of reaction tubes and pipette tips. The liquid of the pooled extracts is evaporated in a centrifugal evaporator. If the volatile salt ammonium bicarbonate was used for the basic extraction, it is partially removed in the drying process. The dried peptides can be stored at -20 °C for at least six months.

=== 1990s === In the early 1990s, Wolverine featured as a prominent character in X-Men vol. 2, initially written by Claremont and illustrated by Jim Lee. The first issue of this series is the highest selling comic book issue in history, selling more than eight million copies. During this period, Wolverine regularly appeared in cover stories for the anthology series Marvel Comics Presents, due to a mandate from Marvel's sales department, which noticed that sales of the series were always higher for issues in which Wolverine was featured. Among these stories was "Weapon X", written and drawn by Windsor-Smith, serialized in issues #72–84 (1991). The story depicts Wolverine's past, how adamantium was grafted to his skeleton, and his experience of extreme psychological and physical trauma. Subsequent Wolverine stories in Marvel Comics Presents were often illustrated by Sam Kieth and had a more psychedelic aesthetic and storytelling style. Wolverine returned to his original blue-and-yellow costume in this period. Wolverine starred in a popular new story arc in X-Men after Claremont's departure, plotted by Byrne and Lee, that revealed more about Wolverine's past and the consequences of the Weapon X program.

=== Metabolism === Ibutilide has a high systemic plasma clearance that closes to the hepatic blood flow (29mL/min/kg). Its metabolic pathway is via liver's cytochrome P450 system by isoenzymes other than CYP3A4 and CYP2D6 by which the heptyl side chain of ibutilide is oxidized. With eight metabolites are detected in the urine, however, only one is an active metabolite that shares the similar electrophysiologic property of the Class III antiarrhythmic agents. The plasma concentration of this metabolite is only less than 10% of ibutilide.

Sources: en.wikipedia.org

Supporting material

=== Wound healing === Research on novel drug formulations for the delivery of doxycycline in wound treatment is expanding, focusing on overcoming stability limitations for long-term storage and developing consumer-friendly, parenteral antibiotic delivery systems. The most common and practical form of doxycycline delivery is through wound dressings, which have evolved from mono- to three-layered systems to maximize healing effectiveness. Research directions on the use of doxycycline in wound healing include the continuous stabilization of doxycycline, scaling up technology and industrial production, and exploring non-contact wound treatment methods like sprays and aerosols for use in emergencies and when medical care is not readily accessible.

The hypothalamus has a central neuroendocrine function, most notably by its control of the anterior pituitary, which in turn regulates various endocrine glands and organs. Releasing hormones (also called releasing factors) are produced in hypothalamic nuclei then transported along axons to either the median eminence or the posterior pituitary, where they are stored and released as needed.

=== Spectrum of activity === Like other third-generation cephalosporins, ceftriaxone is active against Citrobacter spp., Serratia marcescens, and beta-lactamase-producing strains of Haemophilus and Neisseria. However, unlike ceftazidime and cefoperazone, ceftriaxone does not have useful activity against Pseudomonas aeruginosa. It is generally not active against Enterobacter species, and its use should be avoided in the treatment of Enterobacter infections, even if the isolate appears susceptible, because of the emergence of resistance. Some organisms, such as Citrobacter, Providencia, and Serratia, have the ability to become resistant through the development of cephalosporinases (enzymes that hydrolyze cephalosporins and render them inactive). Although not being used as first line therapy against Staphylococcus aureus, ceftriaxone retains activity against isolates of methicillin-susceptible S. aureus and is used in clinic for infections sustained by this bacterium. In this case the dose should be doubled (e.g. 2 g intravenously every 12 hours).

Sources: en.wikipedia.org

Frequently asked questions

Is BPC-157 a naturally occurring peptide?

It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.

What does the number 157 in the name indicate?

It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.

Does the molecule contain sulfur or disulfide bonds?

No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.

Is BPC 157 a natural substance?

It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.

Network